Wegovy is the first drug in India approved for both weight management and risk reduction of major adverse cardiovascular events in individuals with established heart disease.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, though it is exploring oral semaglutide for obesity.

Currently, two criteria must be met to qualify for the prescription. Firstly, a BMI of 40 or over is required, however, if ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

By listening to daily nine-minute audio sessions, it claims, your brain is gently rewired to reduce cravings, boost ...

Irrespective of what we don’t know, the advent of Mounjaro as a substitute for self-control and willpower is entirely in keeping with our labour-saving, quick-fix culture. Why worry when we now have ...

Mounjaro has been accessible in specialist NHS weight loss clinics since March. Another weight loss medication, Wegovy, also ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

It’s a shot at better health that comes with a promise to help shed the pounds. Demand for drugs like Ozempic, Wegovy, Mounjaro and Zepbound continues to grow. FILE – Donna ...

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...